Health Trials

Recurrent Supratentorial Glioblastoma

2

Review clinical trials related to Recurrent Supratentorial Glioblastoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood \[CB\]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.

Participants needed: 25
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jan 23, 2026Locations: 1
Eligibility criteria

Signed and dated informed consent. [+8]

Has received prior therapy with Gliadel or bevacizumab. [+27]

Read more
Status: Recruiting

Lerapolturev (PVSRIPO) in GBM

The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.

Participants needed: 92
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Darell BignerUpdated: Aug 17, 2025Locations: 1
Eligibility criteria

Age ≥ 18 years old at the time of entry into the study. [+15]

Females who are pregnant or breast-feeding [+20]

Read more